Therefore, antagonists of LPA1/3 and ATX may be feasible therapeutic strategies for inhibiting prostate cancer-induced lymphangiogenesis and therefore prevent metastasis-related cancer deaths. Here, LPAR1 is linked to prostate carcinoma.